Imaging technique could enable surgeons to see and remove malignant tumours with ease
Researchers have developed a new imagining technique that could enable surgeons to clearly see malignant growth that is often difficult to completely eliminate. The technique uses a synthetic version of a compound found in scorpion venom.
The new imagining technique uses a special high-sensitivity near-infrared camera, along with the imaging agent tozuleristide or BLZ-100. The agent contains a synthetic version of an amino acid compound found in scorpion venom.
Like the natural form of the compound, the synthetic version is not toxic and binds to tumour cells. It is attached to a fluorescent dye that glows when stimulated by a near-infrared laser.
Viewed through the cameras, the imaging agent might allow neurosurgeons to detect the boundaries between tumours and healthy brain tissue during surgery, improving the opportunity for surgeons to remove tumour cells while sparing normal brain tissue.
With this fluorescence, you see the tumour so much clearer because it lights up like a Christmas tree, said senior author of the study.
This is important because of the sprawling nature of gliomas, the type of brain tumours imaged during the trial. Gliomas are highly lethal and comprise about 33 % of all brain tumours.
They fan infiltrate brain tissue with tentacle-like structures, making them difficult to distinguish from normal brain tissue. They typically do not respond to traditional therapies such as chemotherapy and radiation. The key to extending patient survival depends on a surgeon's ability to detect and remove all parts of the tumour.
In the clinical trial, 17 adult patients with brain tumours were given varying doses of BLZ-100 before surgery. Despite the varying amounts of the drug given, the majority of tumours fluoresced, including both high-and-low-grade gliomas.
After surgery, patients were monitored for 30 days. Investigators found that none of the patients had any serious adverse responses to the drug and that the imaging system was safe and could be useful for imaging the brain tumours during surgery.
More clinical trials are needed to further evaluate the safety of the imaging system and demonstrate the system's effectiveness before BLZ-100 can gain approval from the givernment, and the camera used in the trial must be refined before it can be used seamlessly in an operating room. But the researcher said the clinical trial results were promising.
For a surgeon, this seamless integration of fluorescence imaging into the surgical microscope is very appealing, he said.
Unlike other experimental systems that are bulkier or rely on multiple cameras, the new imaging system uses a single camera that takes both near-infrared and while-light images by alternating between a laser and normal white lights at very high speeds. This technology enables surgeons to easily switch back and forth between normal vision using a surgical microscope and fluorescent super-vision on a nearby monitor, in real time.
The next phase of this research, already underway, is a clinical trial involving paediatric brain tumours. This trial will serve as a data set for potential government approval. A similar adult clinical trial is also being planned.
This technique in this study holds great promise not only for brain tumours but for many other cancer types in which we need to identify the margins of cancers. The ultimate goal is to bring greater precision to the surgical care we provide to our patients, said the doctor.
FOR
CROCHET DESIGNS
https://gscrochetdesigns.blogspot.com
The new imagining technique uses a special high-sensitivity near-infrared camera, along with the imaging agent tozuleristide or BLZ-100. The agent contains a synthetic version of an amino acid compound found in scorpion venom.
Like the natural form of the compound, the synthetic version is not toxic and binds to tumour cells. It is attached to a fluorescent dye that glows when stimulated by a near-infrared laser.
Viewed through the cameras, the imaging agent might allow neurosurgeons to detect the boundaries between tumours and healthy brain tissue during surgery, improving the opportunity for surgeons to remove tumour cells while sparing normal brain tissue.
With this fluorescence, you see the tumour so much clearer because it lights up like a Christmas tree, said senior author of the study.
This is important because of the sprawling nature of gliomas, the type of brain tumours imaged during the trial. Gliomas are highly lethal and comprise about 33 % of all brain tumours.
They fan infiltrate brain tissue with tentacle-like structures, making them difficult to distinguish from normal brain tissue. They typically do not respond to traditional therapies such as chemotherapy and radiation. The key to extending patient survival depends on a surgeon's ability to detect and remove all parts of the tumour.
In the clinical trial, 17 adult patients with brain tumours were given varying doses of BLZ-100 before surgery. Despite the varying amounts of the drug given, the majority of tumours fluoresced, including both high-and-low-grade gliomas.
After surgery, patients were monitored for 30 days. Investigators found that none of the patients had any serious adverse responses to the drug and that the imaging system was safe and could be useful for imaging the brain tumours during surgery.
More clinical trials are needed to further evaluate the safety of the imaging system and demonstrate the system's effectiveness before BLZ-100 can gain approval from the givernment, and the camera used in the trial must be refined before it can be used seamlessly in an operating room. But the researcher said the clinical trial results were promising.
For a surgeon, this seamless integration of fluorescence imaging into the surgical microscope is very appealing, he said.
Unlike other experimental systems that are bulkier or rely on multiple cameras, the new imaging system uses a single camera that takes both near-infrared and while-light images by alternating between a laser and normal white lights at very high speeds. This technology enables surgeons to easily switch back and forth between normal vision using a surgical microscope and fluorescent super-vision on a nearby monitor, in real time.
The next phase of this research, already underway, is a clinical trial involving paediatric brain tumours. This trial will serve as a data set for potential government approval. A similar adult clinical trial is also being planned.
This technique in this study holds great promise not only for brain tumours but for many other cancer types in which we need to identify the margins of cancers. The ultimate goal is to bring greater precision to the surgical care we provide to our patients, said the doctor.
THIS IS ONLY FOR INFORMATION, ALWAYS CONSULT YOU PHYSICIAN BEFORE
HAVING ANY PARTICULAR FOOD/ MEDICATION/EXERCISE/OTHER REMEDIES.
PS-
THOSE INTERESTED IN
RECIPES ARE FREE TO VIEW MY BLOG-
https://gseasyrecipes.blogspot.com/
FOR INFO ABOUT KNEE
REPLACEMENT, YOU CAN VIEW MY BLOG-
https:// kneereplacement-stickclub.blogspot.com/
Labels: amino acid, Brain tumor, easily, gliomas, high-sensitivity near-infrared camera, imaging agent tozuleristide BLZ-100, malignant, new imaging technique, remove, scorpion venom, synthetic version, tumours
posted by G S Iyer at 9:21 AM
0 Comments:
Post a Comment
<< Home